Human-derived, disease-relevant targets for kidney disease

Fibrocor Therapeutics is revolutionizing the fight against fibrosis with a first-in-class pipeline that targets the disease at its roots. By blocking fibroblast activation through two critical mechanisms, cell surface receptor inhibition and nuclear import disruption, Fibrocor is tackling the drivers of fibrosis with precision and power.

Our initial focus is on Alport Syndrome and Autosomal Dominant Polycystic Kidney Disease (ADPKD), two severe, genetically-driven kidney diseases with no disease-modifying treatments. They often leave patients facing dialysis and transplantation in early adulthood.

But this is just the start. With a biomarker-driven strategy grounded in human biopsy transcriptomic analysis, Fibrocor’s therapies could unlock future applications across a spectrum of fibrotic diseases in several organs – including the kidneys, liver and lungs.

In diseases of fibrosis, excessive scar tissue formation disrupts normal organ function, leading to impairment and eventually failure. Existing treatment options are limited, tending to focus on ameliorating symptoms rather than tackling the upstream causes of fibrosis. The situation is complicated by the fact disease is often diagnosed late and there is a high degree of disease heterogeneity.

Molecular-Clinical interface

Longitudinal biobank samples correlated with fibrotic pathology, clinical outcome.

Tissue-cell-disease specificity

RNA-seq analysis for target discovery

Focus on novel tractable targets

Fibrosis Molecular pathways, genomic association and key biological insights.

Validation of key candidate compounds

Validated in the most difficult models of fibrosis / kidney disease. Specifically validated in vivo disease models of Alport, Syndrome, AADPKD and, UUO

Superior Drug Profile(s)

First-in-class candidates, Extremely potent, selective, and excellent safety profile and margins

Patient-derived disease driven
insights at the heart of innovation

Thanks to exclusive access to one of the world’s largest fibrosis tissue biobanks containing kidney, liver, and lung biopsies, Fibrocor has been able to gain novel mechanistic insights and identified disease-relevant, druggable targets from long-term biopsies / biobank work into the underlying mechanisms of fibrosis and made significant strides in the field.

These biobanks, which are connected to best-in-class longitudinal medical records, have provided Fibrocor with invaluable patient information for research and development. They underpin our biomarker-driven strategy and have enabled us to identify novel disease targets to develop a robust pipeline of first-in-class therapeutics.

Our exceptional drug candidates have progressed seamlessly into pre-clinical assessment, paving the way for transformative advancements in fibrosis treatment.


Fibrocor Pioneers a Novel Approach

We collaborate with proven scientific experts to ensure the highest scientific rigor and expertise for target validation and candidate identification. We harness the collective knowledge and insights of unique ecosystem to identify disease drivers and assess their novelty, relevance, and drugability. Thorough validation of these targets was performed using cell and animal models, ensuring that only the most promising candidates move forward in our drug discovery pipeline.

We target key mediators of kidney pathology that we identified by interrogating the largest human kidney disease biobank

new-graphic-homepage
Halting disease progression by targeting fibroblast activation and collagen production